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Case Report
INTRODUCTION
Sensorineural hearing loss can have various causes, and it is 
mostly irreversible. However, it can be managed with treatment 
in some instances such as autoimmune hearing loss (1, 2). There-
fore, in cases of atypical sensorineural hearing loss, such as hear-
ing loss that progresses relatively rapidly, or when neurologic 
signs coexist, the possibility of reversible causes should not be 
ruled out. Also, in order to perform a proper evaluation, otolo-
gists should be aware of the potential causes of reversible senso-
rineural hearing loss. 
  Pachymeningitis is an uncommon disorder characterized by 
localized or diffuse thickening of the dura mater, and is rarely 
reported to lead to sensorineural hearing loss (3-6). Even though 
pachymeningitis is a potentially treatable cause of sensorineural 
hearing loss (4-6), it is quite unfamiliar to otologists and difficult 
to diagnose.
  Here, we present the case of a patient who had rapidly pro-
gressive, bilateral sensorineural hearing loss due to hypertrophic 
pachymeningitis. It was associated with high serum levels of 
myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-
ANCA).
Hypertrophic pachymeningitis is a progressive disease resulting in a diffuse thickening of dura mater due to inflammation, 
tumor or autoimmune diseases, but most cases are idiopathic. It is seldom reported to be related to sensorineural hearing 
loss, but it can cause sensorineural hearing loss which can be potentially reversed through treatment. Here, we report the 
case of a 54-year-old woman who had progressive, bilateral, worse in the left, sensorineural hearing loss and visual distur-
bance with an accompanying headache over several months. Brain MRI showed diffusely thickened dura mater, highly en-
hanced after gadolinium administration, which was consistent with pachymeningitis. It was assumed to be related to auto-
immune pathogenesis on the basis of elevated serum myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) 
titers. After empirical steroid and cyclophosphamide therapy, auditory impairment improved, especially in the high frequen-
cy region of the pure tone audiogram, and significant improvement in the word recognition test. Moreover, a follow-up MRI 
revealed much decreased enhancement of the dura mater, and the MPO-ANCA titer decreased to within the normal range. 
In the case of rapidly progressive sensorineural hearing loss or hearing impairment accompanying other cranial neuropa-
thy, pachymeningitis should be taken into consideration, and brain MRI with gadolinium enhancement is the best method 
of detecting it. Also, to ensure proper treatment, a cautious evaluation including an ANCA work-up should be performed. 
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CASE REPORT
A 54-year-old woman presented with a progressive visual dis-
turbance and hearing impairment, especially in the left ear, over 
the previous month. She also complained of recent intensifica-
tion of a throbbing headache in her left fronto-temporal area 
that had been present for 6 months. 
  An audiologic test revealed bilateral, down-sloping, moderate, 
sensorineural hearing loss with a mean threshold of 50 dB in the 
pure tone audiogram (Fig. 1A). Word recognition scores were 
100% in the right ear and 24% in the left. Ophthalmic exami-
nation showed both peripapillary edema and atrophy, which was 
consistent with optic neuropathy. Other neurologic examinations 
yielded normal findings.
  Laboratory tests showed an elevated erythrocyte sedimenta-
tion rate (ESR) to 47 mm/hour (normal range, 0 to 20 mm/hour), 
a C-reactive protein (CRP) level up to 4.66 mg/dL (normal range 
<0.8 mg/dL), and normal cerebrospinal fluid (CSF). 
  Brain magnetic resonance imaging (MRI) revealed diffuse 
thickening of meninges which appeared hypodense and isoin-
tense on T1 and T2 weighted images (Fig. 2). The meninges were 
markedly enhanced after gadolinium administration (Fig. 3A), 
which was consistent with hypertrophic pachymeningitis.
  A chest X-ray and chest computed tomography showed no 
evidence of silicosis or sarcoidosis or recent tuberculosis. Posi-
tron emission tomography-computed tomography (PET-CT) and 
tests for tumor markers were unremarkable. Upon immunologi-
cal investigation, autoimmune antibodies were found to be in 
the normal range, except for an elevated serum MPO-ANCA (an 
autoantibody titer [AAU] of 388; normal range, 0 to 150 AAU). 
A diagnosis of hypertrophic pachymeningitis associated with a 
high serum level of MPO-ANCA was made. Treatment was start-
ed empirically with high dose steroids (1 mg/kg) and cyclophos-
phamide (Alkyloxan, Choong Wae Pharm, Seoul, Korea) 1.5 mg/
kg. During the administration of steroids and cyclophosphamide, 
her headache gradually subsided. 
  Over a 4-month treatment period with steroids and cyclo-
Fig. 1. Pure tone audiograms and word recognition scores before 
and after treatment. Initial pure tone audiogram (A). Pure tone au-
diogram after a 4-month period of steroid and cyclophosphamide 
treatment. Hearing improvement was detected, especially in the 
high frequency region (arrow) (B). Serially checked word recogni-
tion scores in the left ear after steroid and cyclophosphamide treat-
ment (C). Note that the word recognition score went up daily after 
steroid administration and in month 4 it reached 100%. On the oth-
er hand, the word recognition score in the right ear was 100% in 
every test.  
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Fig. 2. Initial brain MRI. Axial T1-weighted image shows hypo-in-
tense thickened dura mater (A). Axial T2-weighted image shows iso-
intense dura mater with hyperintense border (B).Lim E-J et al.: Reversible Hearing Loss in Pachymeningitis    157
phosphamide, visual loss and hearing impairment gradually im-
proved. On repeat audiologic testing, the pure tone threshold 
was partially improved when compared with the initial pure 
tone audiogram, especially in the high frequency region (Fig. 1B) 
and there were much improved results in word recognition 
scores (Fig. 1C). Also, MRI showed less thickened dura mater 
and diffuse regression of dural enhancement (Fig. 3B, C). The 
MPO-ANCA titer gradually decreased to be within the normal 
range (normal range, 0 to 150 AAU) (Fig. 4). 
  So far, the patient has been on steroids and cyclophosphamide 
at a maintenance dose (steroid 10 mg; Alkyloxan 50 mg per day). 
During the follow up period of 1 year, her symptoms remained 
well-controlled and there was no evidence of recurrence of the 
problem according to serial MRI scans and MPO- ANCA titers.
DISCUSSION
Hypertrophic pachymeningitis is a progressive disease resulting 
in a diffuse thickening of the dura mater. It is caused by inflam-
mation, tumor or autoimmune diseases such as tuberculosis, 
syphilis, sarcoidosis, Wegener’s granulomatosis, and rheumatoid 
arthritis, but mostly it is idiopathic (3, 7). Recently, more research 
on the relationship between pachymeningitis and autoimmune 
pathogenesis has been carried out. Moreover, there have been 
several reports about pachymeningitis with autoimmune anti-
body. In particular, the relationship between ANCA-positive 
pachymeningitis and vasculitis has been discussed (8-10). In our 
case, MPO-ANCA related autoimmune pathogenesis caused 
thickening of the dura mater near the tentorium cerebella.
  ANCAs have been classified as cytoplasmic (c-ANCA) or peri-
nuclear (p-ANCA) based on their immunofluorescence patterns. 
The antigens responsible for these patterns are proteinase 3 (PR3) 
for c-ANCA and MPO for p-ANCA (11). Since Falk and Jen-
nette (8) first identified MPO-ANCA, it has been used for the 
diagnosis of vasculitis-associated disease such as Churg-Strauss 
syndrome and microscopic polyangitis (12).  Also, it was report-
ed that the titer of MPO-ANCA decreases as the disease gradu-
ally improves through immunosuppressive treatment. Hence, it 
is suggested that an MPO-ANCA titer can be used as a monitor-
ing marker of the disease’s activity in such patients (12). In this 
case, the thickness of the meninges and MPO-ANCA titer cor-
responded relatively well, so her MPO-ANCA titer was checked 
regularly to monitor the disease. 
  To diagnose pachymeningitis, MRI with gadolinium enhance-
ment is the most sensitive diagnostic imaging modality, and 
shows the relationship between the inflammatory degree of the 
Fig. 4. Changes in myeloperoxidase-antineutrophil cytoplasmic anti-
body (MPO-ANCA) titer during steroid and cyclophosphamide treat-
ment. Note that the initial high titer of MPO-ANCA (388AAU) de-
creased to within the normal range as treatment was maintained. 
Brain MRI scans were done at 4 and 9 months after treatment.
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Fig. 3. The gadolinium enhanced T1-weighted axial and coronal 
images. Initial images. They demonstrate diffusely enhanced thick 
dura mater around cerebellopontine angle (arrow) (A). After 
4-month steroid and cyclophosphamide treatment (B). After 
9-month steroid and cyclophosphamide maintenance (C). Note 
that diseased dura mater (arrow) became less thickened com-
pared with initial MR image as treatment was maintained.
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lesion and the clinical outcome, as well as the prognosis (3, 7). 
In MR imaging, T1-weighted images show iso- or hypo-intense 
thickened dura mater, and T2-weighted images show hypoin-
tense dura mater of fibrous reacting tissue surrounded by a thin 
hyperintense border attributed to the acute inflammatory pro-
cess. Distinctively, meninges are highly enhanced after a contrast 
injection (7). 
  In pachymeningitis, cranial nerve involvement is of concern 
due to high intracranial pressure resulting from thickened dura 
mater; or it may be directly caused by small-vessel vasculitis or 
indirectly by the inflammatory process of the surrounding soft 
tissue or of the meninges? (13). In most cases, optic nerve in-
volvement is reported along with headache (3, 7, 14), but 8th 
nerve involvement is seldom reported (4-6). 
  Our patient showed auditory impairment, which was unusual. 
Generally in ANCA-associated vasculitis, it is assumed that small 
vessels are impaired in the inner ear, which causes sensorineural 
hearing loss bilaterally (1). However, in this case, the patient 
complained of unilateral hearing impairment, and the word rec-
ognition score in that side was poorer than expected. Several 
studies show that ordinary tone and speech audiometry yields 
little diagnostic information about lesions (15-17). However, ret-
rocochlear pathology would be suspected in the presence of a 
significant discrepancy in word recognition score between two 
ears or a lower than expected performance in speech audiome-
try (17-19). In this patient, after steroid treatment, the pure tone 
threshold at three consecutive frequencies (3,000, 4,000, 8,000 
Hz) improved by 28 dB in the left and 16 dB in the right ear, 
and the word discrimination score improved from 26% to 100% 
in the left. Considering that there was a poor word recognition 
score on the ipsilateral side and that its recovery was consistent 
with improvement of the meninges, we suspected that a retroco-
chlear lesion such as fibrous entrapment of auditory nerve due 
to thickened dura mater was involved as well as a cochlear le-
sion due to autoimmune processes.  
  In conclusion, pachymeningitis may cause sensorineural hear-
ing loss that is sometimes reversible. To make an early diagnosis, 
gadolinium enhanced MR imaging and the otologists’ awareness 
of pachymeningitis are important. Moreover, for proper treat-
ment, the causes of pachymeningits should be evaluated, includ-
ing a serologic test, autoimmune test and imaging. In the case of 
atypical sensorineural hearing loss accompanied by multiple cra-
nial nerve palsy or headache, pachymeningitis should be consid-
ered in the differential diagnosis. 
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